Dr. Mikhail Blagosklonny, The Journey of An Innovative Oncologist

Cancer, although considered to be fatal, can be stopped from spreading when caught in the early stages. However, there are numerous cancer patients without access to medicines as traditional treatments cost a pretty penny. Dr. Mikhail Blagosklonny, an oncologist, researcher, and philanthropist, believes that potential life-saving treatments should be available to patients irrespective of their financial situations and he has made consistent attempts to accomplish this goal. Read Mikhail’s plans for Oncology on Healingmagic.net.

A professor at the Oncology at the Rosewell Park Cancer Institute in the state of New York, Dr. Mikhail Blagosklonny has earned a tenure by using a futuristic approach to mentor the next generation of oncologists. As a researcher who has spent uncountable hours researching about additional topics such as aging, he believes that aging and cancer do correlate in more ways than one. His work in both the aging and cancer fields have led to the creation of treatment plans that would otherwise be left undiscovered. This innovative oncologist has once again surprised the world by theorizing, the use of alternative medicines to treat cancer, and the positive effects these alternative drugs can have to slow down the spread of cancerous cells significantly and in some cases help the patient to go into remission.

One of the drugs that, Dr. Mikhail Blagosklonny believes can be used for cancer treatments is Rapamycin. This medicine was initially used as an anti-fungal agent but since Rapamycin had proved to have immunosuppressive and antiproliferative properties, this dissuaded physicians from prescribing it for its original purpose. Visit classroomvoices.org to read more about Mikhail.

Dr. Mikhail Blagosklonny advocates re-purposing this medicine as the same properties can increase the success rates of organ transplants. He believes with conviction that compared to other traditional cancer treatments, Rapamycin is a better choice due to 2 critical reasons. The first is, this medicine displays a minimum amount of toxicity towards organs such as kidneys which is ideal for patients who are recuperating from treatments and surgeries. The second is, the low toxicity property minimizes the possibility of future kidney transplants in patients suffering from the hemolytic-uremic syndrome.

One of the other crucial reasons, Dr. Mikhail Blagosklonny, supports the use of rapamycin is because it can treat Lymphangioleiomyomatosis (LAM), a rare form of lung disease that affects women who are between the age of 20 and 35 years. Rapamycin can also be utilized to coat coronary stents and prevent the need for a repeated procedure due to additional incidents of stenosis. According to Dr. Mikhail Blagosklonny, there are many real possibilities of using Rapamycin to treat other types of cancers like Tuberous Sclerosis Complex and Facial Angiofibroma.

Currently, Dr. Mikhail Blagosklonny is researching about additional uses of Rapamycin to treat other ailments such as Alzheimer’s disease and Muscular Dystrophy all while increasing the longevity of patients. He is dedicated to finding a cost-effective and efficient treatment plan to target and eliminate cancer cells without harming the remaining healthy cells in patients with a lower immunity. Being a humanitarian, he hopes that his studies will in a few years help other researchers and medical professionals to combat cancer in a timely and swift manner.

Read: http://inprogressmag.com/mikhail-blagosklonny-the-man-waging-war-against-cancer-and-aging/

1 thought on “Dr. Mikhail Blagosklonny, The Journey of An Innovative Oncologist”

  1. Everyone who has the job in the medical research must have thought of the monster before us. I think basically some of the dissertation writers review we have seen will help to shed more light on the solutions. However most of the concerns would have to be about intentionally helping to implement the new discoveries.

Leave a Reply

Your email address will not be published. Required fields are marked *